Filtrer vos résultats
- 3
- 1
- 4
- 4
- 1
- 1
- 2
- 4
- 4
- 4
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 4
- 4
- 4
- 4
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationHepatology, 2018, 68 (4), pp.1245-1259. ⟨10.1002/hep.30034⟩
Article dans une revue
hal-02648452v1
|
||
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohortsLiver International, 2022, 42 (6), pp.1386-1400. ⟨10.1111/liv.15159⟩
Article dans une revue
hal-03553907v1
|
|||
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyLiver International, 2020, 40 (5), pp.1042-1051. ⟨10.1111/liv.14313⟩
Article dans une revue
hal-03590858v1
|
|||
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 InfectionHepatology, 2018, 68 (1), pp.385A
Article dans une revue
hal-03590861v1
|